HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population

Abstract

HIV-infected patients have an increased risk for both Hodgkin and non-Hodgkin lymphomas. A retrospective cohort of all HIV-infected patients diagnosed with lymphoma in urban clinics from 2000–2013 was evaluated to characterize the distribution and determine effects of sub-type and immunophenotype on survival. Of 160 cases identified, 131 (82%) had complete information and were analyzed. The most common sub-types were diffuse large B cell (41%), Burkitt (21%) and Hodgkin lymphoma (18%). Advanced (78% stage III/IV) and extranodal disease (82%) at presentation were common. CD20 was the most commonly expressed immunophenotypic marker (89%). Overall mortality rate was high (26.1 per 100 person-years). Lower mortality was noted in CD10 + and CD20 + lymphomas, but differences were not statistically significant. After adjustment, low CD4 count (≤ 200) at diagnosis was associated with higher mortality (adjusted hazard ration (AHR) = 1.75; 95% CI = 1.00–3.61). Mortality in this cohort of patients with HIV-associated lymphomas was high and exceeds that from published data from the general population.

Keywords::

• HIV
• AIDS
• lymphoma
• non-Hodgkin lymphoma
• AIDS-defining cancer

Acknowledgments

At the time of the study, DJR was supported by a Paul Calabresi Clinical Oncology Training Program award (K12 CA126849) and AFR was supported by a Career Development Award for Building Interdisciplinary Research Careers in Women's Health (K12 HD043489-12). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

This data was presented in part at the 16^th Annual International Meeting of the Institute of Human Virology at the University of Maryland School of Medicine in September 2014.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal